Cabaletta Bio, Inc.
NASDAQ:CABABiotechnology
+$0.04 today
- Market cap
- $227.58M
- Beta
- 3.23
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$1.57
Volume 4.13M
Average 3.33M
CABA Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Cabaletta Bio, Inc.NASDAQ: CABA
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents falls 11.5% from a year ago
Cash & equivalents stood at $116.64M at the end of Q1 FY2026, down 11.5% from a year earlier and up 40.6% from the prior quarter. Over 3 fiscal years it compounded at +0.6% a year.
Context
- Cash & equivalents amounted to 78.7% of total assets at the end of Q1 FY2026, down 1.1 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -11.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 82.98M USD
- Year-over-year change
- -49.4%
- 4-year CAGR
- -9.2%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 82.98M | -49.4% |
| FY2024 | 2024-12-31 | 163.96M | -15.2% |
| FY2023 | 2023-12-31 | 193.24M | +136.8% |
| FY2022 | 2022-12-31 | 81.61M | -33.2% |
| FY2021 | 2021-12-31 | 122.22M | — |
Cash & Equivalents vs competitors
How CABA compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -11.5% is the 5th highest of 11, against a peer median of -23.7%.
- Cash & equivalents amounts to 78.7% of total assets for CABA, versus a peer median of 31.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $123.65M USD | -10.8% | +1.2% | 82.8% | |
| Mar 2026 | $116.64M USD | -11.5% | +0.6% | 78.7% | |
| Mar 2026 | $105.42M USD | +266.1% | +210.6% | 32.3% | |
| Mar 2026 | $90.77M USD | -24.6% | -21.3% | 25.9% | |
| Mar 2026 | €81.17M EUR | -43.2% | -0.9% | 81.9% | |
| Mar 2026 | $79.32M USD | -33.6% | -47.1% | 29.7% | |
| Dec 2025 | A$72.75M AUD | -1.5% | -5.5% | 49.4% | |
LXEOLexeo Therapeutics, Inc. Common Stock | Mar 2026 | $71.77M USD | +148.2% | -6.6% | 28.7% |
| Mar 2026 | $48.54M USD | -22.8% | -30.4% | 43.9% | |
| Mar 2026 | $32.19M USD | -43.4% | +48.7% | 12.5% | |
| Mar 2026 | $30.31M USD | -28.6% | -5.8% | 7.7% | |
| Peer median (excluding CABA) | — | -23.7% | -5.7% | 31.0% | |
Competitors are the stored peer set for CABA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 122.22M | 81.61M | 193.24M | 163.96M | 82.98M |
| Short-term Investments | 0 | 24.94M | 48.01M | 0 | 50.62M |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 1.97M | 2.29M | 0 | 2.71M | 5.27M |
| Total Current Assets | 124.54M | 108.83M | 244.49M | 166.68M | 138.87M |
| Property, Plant & Equipment (Net) | 1.44M | 7.57M | 7.45M | 16.08M | 21.05M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 357K | 565K | 1.71M | 6.23M | 5.16M |
| Total Non-current Assets | 1.8M | 8.13M | 9.16M | 22.31M | 26.21M |
| Total Assets | 126.34M | 116.97M | 253.65M | 185.05M | 165.08M |
| Account Payables | 2.33M | 2.46M | 4.55M | 4.92M | 6.64M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 3.07M | 1.33M | 40K | 8.36M | 9.8M |
| Total Current Liabilities | 8.38M | 9.49M | 15.99M | 27.09M | 50.15M |
| Long-term Debt | 0 | 0 | 0 | 0 | 2.88M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 0 | 2.96M | 1.46M | 5.63M | 2.88M |
| Total Liabilities | 8.38M | 12.45M | 17.45M | 32.71M | 53.03M |
| Common Stock | 0 | 0 | 0 | 1K | 1K |
| Retained Earnings | (112.59M) | (165.56M) | (233.24M) | (349.1M) | (516.96M) |
| Accumulated OCI | 0 | (47K) | 39K | 0 | 25K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 117.96M | 104.52M | 236.2M | 152.34M | 112.05M |
| Total Debt | 0 | 5.14M | 5.02M | 15.6M | 27.1M |
| Net Debt | (122.22M) | (76.47M) | (188.22M) | (148.36M) | (55.88M) |
Cabaletta Bio, Inc.
NASDAQ:CABA
Intrinsic Alpha fair value
Locked
Current Price
$1.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.